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Making waves: how ultrasound-targeted drug
delivery is changing pharmaceutical approaches
Lauren J. Delaney,
Noreen J. Hickok

a
b
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a

Administration of drugs through oral and intravenous routes is a mainstay of modern medicine, but this
approach suﬀers from limitations associated with oﬀ-target side eﬀects and narrow therapeutic
windows. It is often apparent that a controlled delivery of drugs, either localized to a specific site or
during a specific time, can increase eﬃcacy and bypass problems with systemic toxicity and insuﬃcient
local availability. To overcome some of these issues, local delivery systems have been devised, but most
are still restricted in terms of elution kinetics, duration, and temporal control. Ultrasound-targeted drug
delivery oﬀers a powerful approach to increase delivery, therapeutic eﬃcacy, and temporal release of
drugs ranging from chemotherapeutics to antibiotics. The use of ultrasound can focus on increasing
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tissue sensitivity to the drug or actually be a critical component of the drug delivery. The high spatial
and temporal resolution of ultrasound enables precise location, targeting, and timing of drug delivery
and tissue sensitization. Thus, this noninvasive, non-ionizing, and relatively inexpensive modality makes
the implementation of ultrasound-mediated drug delivery a powerful method that can be readily
translated into the clinical arena. This review covers key concepts and areas applied in the design of
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diﬀerent ultrasound-mediated drug delivery systems across a variety of clinical applications.
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Introduction
The delivery of drugs through oral and parenteral routes has
enjoyed long success, but as disease treatments are refined, it is
often apparent that a controlled delivery of drugs, either
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localized to a specific site or during a specific time, can increase
eﬃcacy and bypass problems with systemic toxicity. One
approach that has increased delivery eﬃciency and therapeutic
eﬃcacy of drugs ranging from chemotherapeutics to antibiotics
involves ultrasound technology improvements. These improvements often focus on increasing tissue sensitivity to the drug or
can act as critical components of the drug delivery. In this
review, we will focus on methods that allow non-invasive,
spatiotemporal-specific drug delivery.
Ultrasound-targeted drug delivery (UTDD) builds upon the
vast literature exploiting drug delivery systems. Specifically,
local placement of drug elution systems, radioactive beads,
etc., has long been a mainstay in drug delivery systems.1–3
These first generation devices begin elution/decay from the
moment of placement. However, drug concentrations are
rapidly depleted, usually undergoing an exponential decrease
in the concentration of the eluting drug. Such systems are
exemplified by antibiotic-laden bone cement that is used to
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treat peri-prosthetic joint infections,4 antibiotic-impregnated
coatings on penile implants,5 and transarterial chemoembolization,6 among others. Importantly, these drug delivery systems
only achieve concentrations in the high therapeutic range for short
durations—on the orders of hours and perhaps out to several
weeks.7 Drug delivery devices of increasing sophistication aim for
temporally- and spatially-controlled delivery of drugs, often with
triggers that rely on a biological input.
To respond to this need for spatiotemporally controlled drug
delivery, materials that release drug based on a response to a
biological signal have been devised,8,9 and include pathwaysensitive,10–12 pH-sensitive,13 and even electrical14 triggering.
However, all of these techniques are limited in clinical situations as they suffer from significant shortcomings associated
with the transition from the well-defined in vitro to the complex
in vivo environments. Prolonged drug release has been achieved
through use of layer-by-layer coatings,15 where the duration of
release can be tailored depending on the numbers of layers and
their dissolution characteristics. Nonetheless, in all of these
examples, the complete system is always implanted with limited or no external control.
To generate an external trigger, our group and others have
turned to ultrasound waves. Ultrasound is a widely used
modality for imaging and is selectively used for therapeutic
applications such as extracorporeal shockwave lithotripsy,
demonstrating safety and utility in the clinical arena.16 In
terms of drug delivery, ultrasound allows precise temporal
control of release, which is usually in real-time during the
insonation period.17 In addition to temporal control, the high
spatial resolution of ultrasound (on the order of mm) enables
precise targeting, and the noninvasive, non-ionizing, and
relatively inexpensive nature of ultrasound makes the implementation of UTDD more likely to be translated to clinical
use.18–20
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Basics of ultrasound physics
Ultrasound imaging is characterized by the transmission of a
short cyclic pressure wave (sound) (420 kHz) from a transducer
through the body. When transmitted waves passing through
the tissues reach a boundary with an impedance mismatch,
some of the energy (typically o1%) is reflected back to the
transducer, while the remaining energy continues to pass
through the tissue until it encounters another boundary or is
absorbed by the body. Reflected waves are used to generate
images. Some characteristics used to describe an acoustic
signal/sound wave include its center frequency in MHz, acoustic pressure amplitude or peak negative (rarefactional) pressure
in Pascals (Pa), pulse length in seconds, pulse repetition
frequency in Hz, duty cycle, (percentage of time acoustic energy
is actually being transmitted), and intensity in W cm 2.21
Clinical ultrasound, administered to patients, is also described
by the mechanical index (MI), a safety index which relates to the
risk of non-thermal damage to the tissue.22
Acoustic parameters can be manipulated to produce conditions that are conducive to UTDD by controlling frequency,
acoustic pressure, intensity, radiation forces, and focal zone.
The frequency of the sound wave determines (1) the depth of
penetration, where lower frequencies allow imaging of deeper
tissues; (2) imaging resolution, since higher frequencies provide higher resolution; and (3) degree of cavitation.23,24 Adjustments to the transducer will modulate the acoustic pressure
and impact the amount of energy that is received by the
imaging target. The sound wave is characterized by the peak
positive pressure (i.e., maximum compressional pressure) and
the peak negative pressure, which is the minimum rarefactional pressure.23,25 Similar to acoustic pressure, the intensity
of the ultrasound wave describes the amount of power carried
by the wave through the medium to which it is applied, and is
sensitive to the density of the target as well as the properties of
the propagation medium.23,26 Intensity can be modulated
through the characteristics of the ultrasound wave pulse (pulse
length, pulse repetition frequency, and duty cycle).27 Radiation
forces are those that occur between the ultrasound wave, target
tissues, and/or target particles, and are neither thermal nor
cavitational. When used with particles, the ultrasound wave
produces a unidirectional force along the path of the beam that
pushes the particles against the blood vessel walls, and the
magnitude of that force is proportional to the acoustic frequency and intensity.23,28 Finally, ultrasound waves can also be
administered in either a focused or a non-focused fashion.
Historically, it was believed that it was best to use focused
ultrasound as the highest intensity is found at the focal zone.29
Certain therapeutic techniques, such as lithotripsy and liver
tumor and uterine fibroid ablation, now utilize high-intensity
focused ultrasound (HIFU) in order to cause desired physiological changes in the target tissue.30 However, clinical practice
generally uses diagnostic ultrasound with broader unfocused
signals within the FDA limits that produce multiple reflections
across a larger area of interest, avoiding unintended damaging
bioeﬀects (i.e., tissue damage) of a more focused, therapeutic,
high intensity beam.23,31

© 2022 The Author(s). Published by the Royal Society of Chemistry
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The physiological eﬀects induced by ultrasound insonation
have been used in a variety of ways for targeted drug delivery.
Studies of mechanical means for improving drug delivery (i.e.,
ultrasound pressure waves) have demonstrated increased cytotoxicity and drug retention at the tumor site when exposed to
therapeutic ultrasound in vitro (up to a 3-fold increase for
doxorubicin (DOX)) compared to cells that were not
insonated.32,33 Similarly, a limited number of studies have
demonstrated increased antibiotic eﬃcacy against infections using
therapeutic ultrasound.34–37 Increased cytotoxicity is likely due to
increased cell uptake of drug in response to ultrasound-induced
increases in cell membrane permeability.33,34,38 However, augmenting drug delivery via ultrasound insonation is typically more
efficacious when combined with microbubble-based ultrasound
contrast agents (UCA) (Fig. 1); specifically, in the form of
ultrasound-triggered microbubble destruction (UTMD) and
sonoporation.34,39,40

Microbubble cavitation-based drug
delivery
One of the most well-known UTDD methods involves the use of
microbubbles, which generally consist of a gas core encapsulated by a stabilizing shell usually made of lipid, protein, or
polymer. Microbubbles, including micelles and liposomes,
often are used as UCA to enhance image quality, but can also

Fig. 1 Eﬀects of microbubble enhanced ultrasound on the local environment. The depicted scenario includes a tumor bed and an intravenous coadministration of microbubbles and drug, where ultrasound is applied to
the local site of interest. Ultrasound induces cavitation of the microbubbles, resulting in physical eﬀects such as shock waves, microstreaming,
and shear stress. These eﬀects disturb and eventually cause pore formation in the vessel wall and cell membranes as well as greater tumor cell
separation, which allow drugs to penetrate deeper into the tumor bed.
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be used to augment or facilitate drug delivery within the body
as a result of their unique interaction with and response to
acoustic waves. Ideally, microbubbles used for UTDD would be
non-toxic, be injected intravenously, have a diameter of 8 mm or
less to pass freely through the capillary bed, provide acoustic
enhancement, and have appropriate stability to withstand the
duration of administration.41
Broadly, intravenously-injected UCA will reflect ultrasound,
due to the acoustic impedance mismatch between blood and
the gas encapsulated within the UCA (increasing contrast by
more than 20 dB).42,43 The bubbles expand and contract as the
acoustic wave passes, in a phenomenon known as cavitation.44
The degree to which the agent expands and contracts, or
cavitates, is proportional to the pressure rarefaction and
compression of the sound wave, respectively.27,44 Microbubbles generate three distinct modes of behavior in response
to the ultrasound wave that can be utilized for therapeutic applications.34,39,40,45 At low acoustic powers (typically
MI o 0.2), the ultrasound pulses used for imaging cause the
bubbles to vibrate and this can cause small ruptures in cell
membranes locally increasing the delivery of drugs, although
not necessarily causing a regional increase in drug delivery.39
As the acoustic power increases, changes in vasculature permeability, caused by larger ruptures in capillaries leading to the
escape of blood, pooling, and an increase in local drug uptake
(Fig. 1), occur at MI values between 0.2 and 0.8.45–49 This
phenomenon is known as sonoporation and is due to the
UCA oscillations becoming nonlinear (so called stable cavitation) with limited microbubble disruption beginning to emit
low-energy shock waves. This disruption increases markedly as
the acoustic intensity is increased further (generally MI 4 0.8)
when the UCA readily burst producing copious high-energy
shock waves emanating from the microbubbles (so called
inertial cavitation).39,45,46 Cavitation and sonoporation are
improved at lower ultrasound frequencies when the peak
negative pressure is maintained, suggesting the importance
of wave amplitude.50–52 Representative images of a cavitating
and fragmenting microbubble are shown in Fig. 2.53
Disrupting and destroying microbubbles (i.e., UTMD) have
the potential to alter vascular structures such as cell junctions
as well as cell membranes via mechanisms that include radiation force, shock waves, sonoporation, and microstreaming (cf.,
Fig. 1).34,39,45,54–56 As the bubble collapses against a boundary,
fluid will be focused and accelerated through the bubble,
forming a liquid jet in the direction of the boundary that can
travel over 20 mm with an average velocity of roughly 80 m s 1
and pressures up to 60 MPa.44,57 Thus, application of ultrasound will oscillate microbubbles present in the microcirculation and induce mechanisms that increase the local
permeability of the vasculature, allowing the released or coadministered drugs to extravasate into the targeted tissue.
Several mechanisms are known to induce such bioeffects,
including sonoporation and endocytosis for intracellular delivery, disruption or reversible opening of the endothelial cell
junctions, as well as modification of the fenestration pores or
other alterations of the vascular endothelium.45 It is important
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Fig. 2 Optical frame (a–g) and streak (h) images showing the oscillation
and fragmentation of an ultrasound contrast agent microbubble. The
microbubble has an initial diameter of 3 mm (a), and the streak image
(h) shows the changes in the bubble diameter as a function of time and the
ultrasound pressure wave, with the fragmentation occurring during compression (e and f). Reprinted with permission from ref. 53.

to keep in mind that while UCA are typically delivered systemically, the ultrasound pulse can be targeted so that effects can be
localized to the targeted tissue for a desired clinical application
(e.g., cancer treatments, blood brain barrier (BBB) opening,
biofilm disruption, etc.).34,45
Over the last few decades, many iterations of microbubbles
and UCA have been developed with various combinations of
gases (e.g., air, sulfur hexafluoride, and oxygen) and shell
materials (e.g., phospholipids, synthetic polymers, proteins,
and surfactants) with mixed success.43,58,59 Currently, only
three UCA (Optison (GE Healthcare), Definity (Lantheus Medical Imaging), and Lumason/SonoVue (Bracco)) are approved by
the FDA for clinical use in the United States. However, there are
numerous micro- and nano-scale agents at various stages along
the research pipeline that can be used for UTDD. In addition to
co-administration of microbubbles and drug, three general
classes of microbubble technologies have been explored for
drug delivery:60 (1) drug loaded microbubbles; (2) in situ formed
microbubbles from nanodroplets; and (3) targeted microbubbles (e.g., microbubbles with ligands attached for targeting to
cell surface receptors). Therapeutic agents have also been
loaded into microbubbles and UCA for drug delivery without
systemic administration of free drug, aiming to increase bioavailability at the target site, while sparing healthy tissues from
collateral damage from exposure to the drug.27 This concept
relies on ultrasound pressures to induce inertial cavitation and
UCA destruction at the target site, as discussed previously,
resulting in drug release localized to the region of interest.
However, due to the confined volume available for drug loading, the amount of drug that can be incorporated into a
microbubble shell or membrane is limited.60,61 In addition,
attaching or incorporating a drug into the UCA microbubble
shell may alter the biological activity of the drug or the acoustic
capabilities of the UCA.61–63
Lipid-based microbubbles and UCA currently dominate the
UTDD literature, due to their ease of fabrication, flexibility and
versatility, immediate release profile, and commercial
availability.64–66 Briefly, these agents are comprised of a

© 2022 The Author(s). Published by the Royal Society of Chemistry
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monolayer of lipids surrounding a gas core, where both the
lipid and the gas can be selected to influence the behavior and
loading of the agent.64,67 Liposomes are sphere-shaped vesicles
that consist of one or more phospholipid bilayers surrounding
an aqueous liquid core, while micelles are also sphere-shaped
but comprised of a lipid monolayer that assembles itself when
exposed to an aqueous solution. As an alternative to thin-walled
lipid-based agents, a good deal of research is being directed
toward the development of polymer-shelled microbubbles,
since their thicker shells (100–400 nm) can increase drug
loading, which may ultimately improve UTDD. These polymeric
microbubbles can withstand higher ultrasound pressures than
lipid-based microbubbles, with studies showing tolerance of
over 0.54 MPa higher rarefactional pressure levels than phospholipid agents.68 Initial efforts involved the use of natural
polymers, such as alginate and collagen, but have since largely
transitioned to synthetic polymers such as poly(lactic-coglycolic) acid (PLGA) and poly(lactic acid) (PLA).69 Briefly,
fabrication of microbubbles with synthetic polymers generally
involves emulsification of an aqueous phase with a polymeric
solution (in an organic solvent), followed by spray drying or
lyophilization,70–72 or involves a microfluidics approach to
producing monodisperse microbubble populations.73 Aside
from lipid- and polymer-based microbubbles, groups are also
investigating other types of microbubbles and agents, such as
protein- and bioprotein-shelled microbubbles, liposomes, and
micelles, for UTDD applications.74–76

Review

Fig. 3 Ultrasound imaging in contrast enhanced (left) and B-mode (right)
of a human pancreatic cancer xenograft mouse model. (A) Microbubbles
loaded with GEM are visualized (blue arrow) within the tumor (white circle).
(B) The microbubbles and tumor are subjected to a 4 second, 1.35 MI
destructive pulse to induce inertial cavitation and UTDD. (C) An absence of
microbubbles is seen within the tumor, suggesting the destruction of the
GEM-loaded microbubbles following the high-MI ultrasound pulse. Reprinted with permission from ref. 61.

Cancer-related delivery
Microbubbles have been studied as a targeted delivery vehicle
for several types of cancers, with many recent review articles
eloquently displaying the breadth of research in this
area.34,77–80 This review will touch briefly on several recent
efforts, including UTDD and sonoporation techniques. Wu
et al. investigated the efficacy of pluronic polymer micelles,
specifically P123/F127, to generate curcumin-carrying polymeric micelles for UTDD.81 Application and insonation
(1.9 MHz, 0.4 W cm 2, 1 min) of these micelles resulted in
significant inhibition of 4T1 breast cancer tumor growth with a
6.5-fold reduction in tumor weight compared to controls in a
mouse model.81 Combining the concepts of immune shielding
and multi-modal targeting, Jablonowski et al. decorated the
surface of DOX-loaded PLA microbubbles with tumor necrosis
factor-related apoptosis inducing ligand (TRAIL) and polyethylene glycol (PEG).63,82 These microbubbles demonstrated augmented tumoricidal activity after 20 minutes of insonation
(5 MHz, 0.94 MPa) against MDA-MB-231 (up to 80%) and
MCF7 (up to 60%) breast cancer cells in culture, while also
achieving at least 30% decrease in immune activation.63,82
Recently, this group also showed some success in encapsulating gemcitabine within a PLA microbubble for treatment
against MiaPaCa-2 pancreatic cancer cells.61 However, the
in vitro success did not translate into tumor suppression in a
mouse model (Fig. 3), highlighting the limitations of drug
loading capacity within microbubbles.61 In an effort to improve
drug loading and delivery, Teraphongphom et al. demonstrated

© 2022 The Author(s). Published by the Royal Society of Chemistry

the feasibility of loading quantum dots, magnetic iron oxide
nanoparticles, and gold nanoparticles within the shell of PLA
microbubbles, suggesting that these modalities could provide
opportunities for multimodal imaging techniques or
therapeutics.83
Microbubbles can also be used to carry other factors, such as
genes or gases, that can be used to improve cancer treatments.
For example, Du et al. adopted an approach for gene delivery
similar to those used for drug delivery by conjugating magnetic
mesoporous silica nanoparticles carrying pGCMV/eGFP
plasmid DNA to dipalmitoylphosphatidylcholine (DPPC)/
1,2-distearoyl-sn-glycero-3-phosphoglycerol (DSPG)/N-(carbonylmethoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-glycero-3phosphoethanolamine (DSPE-PEG2000) microbubbles.84 In a
xenograft mouse model of ovarian cancer, this approach not
only protected the vector from degradation but also protected
surrounding cells from non-specific cytotoxicity from the vector. Additionally, they were able to maintain the cavitational
properties of the microbubble for UTDD when insonated at
7 MHz with 0.6 MPa and 30% duty cycle for 1 minute.84
Eisenbrey et al. designed ultrasound-sensitive oxygen-loaded
microbubbles stabilized by Span 60 and water-soluble vitamin
E surfactant (SE61 O2) for targeted delivery of oxygen to hypoxic
breast tumors via insonation (4.2 MHz, 2.5 MPa, 4 seconds) in a
mouse model.85,86 By increasing the local tumor oxygenation by
20 mmHg immediately prior to radiation therapy, they achieved
almost triple the amount of tumor radiosensitivity compared to

Mater. Adv., 2022, 3, 3023–3040 | 3027
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Fig. 4 Results from oxygenation study using UTMD of oxygen loaded microbubbles. (A) Average intratumoral oxygenation profiles, demonstrating
sustained pO2 elevation when SE61O2 microbubbles are insonation (black circles), but minimal changes in pO2 levels with insonation of saline injection
(red triangles) or SE61O2 microbubbles without insonation (blue squares). Data points represent mean values, with error bars representing standard
deviation. (B) Mouse survival in days following treatment, where mice treated with SE61O2 bubbles, ultrasound, and 5 Gy radiation (black line) had
significantly increased radiation sensitivity and overall survival. Reprinted with permission from ref. 85.

the hypoxic controls (Fig. 4).85,86 This group also demonstrated
that these SE61 O2 microbubbles were eﬀective against brain
metastases from these breast cancer models, suggesting a wide
applicability of these agents.87 Building upon this work, this
group has also investigated loading lonidamine within these
oxygen-carrying microbubbles to achieve multi-modal UTDD
against hypoxic tumors, including breast and head and neck
cancers.88,89
Significant eﬀorts have also been devoted to sonoporation of
pancreatic ductal adenocarcinoma (PDAC), since this remains a
lethal cancer with an overall five year survival rate of approximately 10% and a median survival for all patients of less than 6
months.90,91 Standard-of-care chemotherapy regimens have
only marginally increased overall survival rates, and thus, are
largely ineﬀective in preventing recurrence and eventual
death.92,93 Recently, Logan et al. developed a novel approach
to loading a combination of drugs within a lipid-based microbubble by creating a drug-laden phospholipid molecule for use
in a one-pot synthesis of a dual-loaded UCA.94 They combined a
solution of chloroform and 1,2-dibehenoyl-sn-glycero-3phosphocholine (DBPC) with another solution of gemcitabine,
phospholipase D, and calcium chloride to generate a
gemcitabine-carrying phospholipid complex that can be used
to form the shell of a lipid microbubble.94 The final microbubble consisted of the lipid-gemcitabine molecule, DSPEPEG2000, and paclitaxel (5 : 1.43 : 2.5 weight ratio) surrounding
a perfluorobutane core, and resulted in a 40% reduction in
tumor growth in a BxPC-3 pancreatic cancer mouse model
when administered in conjunction with ultrasound (1 MHz,
3.5 W cm 2, 0.48 MPa).94 In another approach, Dwivedi et al.
designed a DOX-loaded magneto-liposome-ligated microbubble
complex, where the iron oxide nanoparticles were loaded with
DOX then encapsulated within oligolamellar vesicles,
which were then covalently conjugated to lipid-based microbubbles (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC))/
cholesterol/DSPE-PEG2000-maleimide (60 : 20 : 20 molar ratio)
with a perfluorooctane gas core.95 The resulting magnetoliposome-ligated microbubble complex improved pancreatic
tumor targeting and tumoricidal activity (approximately 80%
reduction in tumor volume) in a pancreatic cancer xenograft
mouse model.95 Additionally, groups are working to utilize
ultrasound to enhance the permeability and drug uptake of

3028 | Mater. Adv., 2022, 3, 3023–3040

PDAC tumors. Using xenograft mouse models of PDAC, Schultz
et al. investigated PDAC sonoporation using all four worldwide
clinically-approved UCA (Optison, Definity, Lumason/SonoVue,
and Sonazoid (GE Healthcare)) and two ultrasound regimens
(2.0 MHz 20 ms pulses at low and high acoustic powers for
10 minutes) to identify the ideal parameters to increase therapeutic eﬃcacy.96 Treatment with high power ultrasound
(ISPTA = 200 mW cm 2) utilizing Sonazoid as the UCA most
consistently caused an increase in permeabilization across
diﬀerent experiments and markers of permeability. The results
from this and other pre-clinical studies indicate that UCA
weaken endothelial cell junctions, increase fenestration sizes,
and can generate minute resealing pores in cells, all of which
can facilitate deeper penetration of chemotherapeutic agents
into the PDAC tumor.48,49,96 A Phase I clinical trial aimed at
augmenting standard-of-care chemotherapy eﬃcacy led to significant improvement in 10 PDAC patients receiving sonoporation treatment compared to 63 historical controls.97,98 The
results included tumor regression in 50% of the patients and
a significant increase in the number of treatments patients
were able to undergo (8.3  6.0 cycles in controls, 13.8  5.6
cycles after sonoporation treatment; p = 0.008). Most importantly, overall survival improved from 8.9 months in the controls to 17.6 months (p = 0.011).97,98 A larger, Phase II clinical
trial is currently underway.99
Infection-related delivery
Research on ultrasound-triggered enhancement of antimicrobials to treat infections is an emerging area for UTDD use.34
Recently, Horsley et al. demonstrated over 16 times greater
intracellular delivery of gentamicin to an in vitro human
bladder organoid model of urinary tract infection when their
DSPC/DSPE-PEG/DSPE-PEG-biotin/1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
(79.5 : 10 : 10 : 0.5 molar ratio) microbubbles decorated with
gentamicin-loaded DSPC/DSPE-PEG liposomes when exposed
to ultrasound (1.1 MHz, 2.5 MPa, 20 s) compared to uninsonated controls.100 Furthermore, twice the amount of delivery
was achieved with liposomes that were insonated but not
conjugated to microbubbles.100 A diﬀerent application for
UTDD that has recently been investigated is improving acute
transplant rejection, such as the study of cardiac transplant

© 2022 The Author(s). Published by the Royal Society of Chemistry
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rejection described by Liu et al.101 This group developed a
DSPC/DSPE-PEG2000 (9 : 1 molar ratio) microbubble loaded
with FK506 anti-rejection drug, and demonstrated both
increased drug delivery (1.64-fold higher) and reduced cardiac
graft rejection (average 4 day prolonged graft survival) in the
group of rats that received both the loaded microbubbles and
insonation with HIFU (1 MHz, 2 W cm 2).101
Studies have shown in vitro and in vivo that 5–10 minutes of
UTMD (80–300 kHz at 0.5–1.0 W cm 2 and a 50% duty cycle,
which is well outside the limits of clinical scanners) via cavitation causes simple biofilms and catheter-associated biofilms to
become more susceptible to vancomycin.35,36,102 The rupture of
UCA microbubbles subjects biofilms to powerful shockwaves,
which transiently permeabilize the cell membrane, increase
antibiotic transport, increase biofilm extracellular matrix porosity, and decrease biofilm thickness.102 While joint infection
rates have been improving, more than 20 000 patients per year
will be diagnosed with bacterial infections of their synovial
fluid.103 Such infections are a significant cause of morbidity
and mortality, and the presence of large (often 2–5 mm in size),
proteinaceous, bacterial biofilm aggregates may be a primary
reason for joint infection antibiotic treatment failures.103 We
tested the clinical applicability of injections of amikacin as well
as Definity microbubbles together with application of UTMD in
a pilot study of Staphylococcus aureus septic arthritis in 12 pig
femorotibial joints (Fig. 5).104,105 Septic joints that received
treatments of amikacin alone or of amikacin with ultrasound
insonation (i.e., without microbubbles) did not resolve the
infection. When UTMD was applied concomitantly with injection of amikacin (4 s destructive pulses at an MI 4 0.6 at 3.5–
5.0 MHz), all five pigs with confirmed infection showed
reduction of bacterial burden to below detectable levels
(p = 0.008). This suggests that administration of antibiotics
with microbubble cavitation could be an efficacious treatment
approach to difficult cases of septic arthritis.104,105
Other application areas
While the BBB maintains the homeostasis of the brain, it also
blocks over 98% of small drugs (o600 Da) and all larger
therapeutic molecules from entering the brain, limiting the
applicability of a large number of drugs.106,107 Focused ultrasound (with peak negative pressures 4200 kPa and transmit
frequencies o2 MHz) and UCA microbubbles (most frequently
Definity) have been used to transiently increase the permeability of the BBB in various pre-clinical settings both paracellularly
and transcellularly, including more recently in primates.108–111
Omata et al. investigated whether the encapsulated gas core
had an effect on the in vivo contrast and cavitation behavior of
drug-loaded lipid microbubbles composed of DSPC, DSPG, and
DSPE-PEG2000 (30 : 60 : 10 molar ratio) during circulation in a
mouse model.112 In their study, perfluoropropane and perfluorobutane were most effective at retaining contrast properties as
well as delivering Evans blue dye as a model drug to the brain
when the agents were insonated at 3 MHz (0.5 W cm 2
intensity) for 3 minutes.112 Interestingly, Shekhar et al. demonstrated effective encapsulation and ultrasound-triggered
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Fig. 5 Ultrasound imaging in contrast enhanced (left) and B-mode (right)
of UTMD in synovial fluid within a septic knee joint in a pig. (A) Microbubbles are visualized (blue arrow) within the septic joint. (B) The microbubbles and joint are subjected to a destructive pulse for UTMD. (C) An
absence of microbubbles is seen within the septic joint, suggesting UTMD
and UTDD following the destructive pulse.

(6 MHz Doppler, MI 0.8 and 220 kHz pulsed, MI 0.47,
10 seconds) delivery of xenon to the brain in a mouse model
using a DSPC/DSPE-PEG2000 (9 : 1 ratio) lipid-shelled microbubble loaded with xenon and octafluoropropane, to help
reduce and stabilize neurologic injury in stroke.113 Most excitingly, since 2018, several small (4–5 patients per study) phase I
safety and feasibility studies on permeabilizing the BBB in
humans using focused ultrasound techniques have been
reported with no serious clinical or radiological side
effects.114–116 A representative image from one of these studies,
demonstrating visible BBB opening, is shown in Fig. 6. In all
three trials, an ultrasound device with 1024 individual transducers operating at a frequency of 220 kHz (ExAblate Neuro;
InSightec) and power ranging from 5.2 to 19.4 W were used
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Fig. 6 MRI images from baseline (a), immediately following HIFU (b), and
24 hours after HIFU (c), demonstrating opening and closure of BBB.
Extravasation and pooling of contrast within the insonated portion of the
frontal lobe is visible immediately following HIFU administration (b, blue
arrow) demonstrating opening of the BBB, but is absent 24 hours later (c)
suggesting BBB closure. Reprinted (modified) with permission from ref.
116.

in conjunction with Definity microbubbles (4 mL kg 1). These
studies pave the way for future large-scale human clinical trials
to investigate efficacy of these methods for ultrasoundaugmented drug delivery to the brain.
Wound healing applications are also gaining attention in
the field of UTDD. For example, Zhu et al. designed a paclitaxelloaded lecithin/cholesterol (3 : 1 weight ratio) microbubble via
film hydration for targeted delivery to a rabbit iliac balloon
injury model, demonstrating nearly doubled drug release
(1 MHz, 1.5 MPa, 10 seconds) and a 30% reduction in vascular
smooth muscle cell viability in the model.117 Similarly, Wang
et al. showed a 10-fold improvement in drug penetration in
stented coronary artery tissue in response to low-intensity
pulsed ultrasound (10–900 kHz, with 0.1–10% acoustic power)
of surfactant-stabilized microbubbles embedded with
paclitaxel-loaded PLGA nanoparticles.118 They showed a 10fold increase in drug retention in a porcine coronary artery
model, providing a good basis for continued research into
precision delivery of antiproliferative drugs to stented vascular
tissue.118 In a theranostic approach, Zhang et al. designed a
PLGA microbubble loaded with simvastatin, and further conjugated their surface with anti-ICAM-1 antibodies that selectively bind to the target site, in order to evaluate and treat
atherosclerosis, showing success with UTDD (450 W positive
pressure amplitude) in a rabbit model.119 UTDD has also been
investigated for delivering nitric oxide to sites of vascular
injury, where nitric oxide is encapsulated within a microbubble
to protect the gas from endogenous scavengers until it is
released at the target site.120 For example, Tong et al. investigated whether insonation (1 MHz, 1 W cm 2, 60 seconds) of
co-injected mesenchymal stem cells and nitric oxide-carrying
1,2-dipalmitoyl-sn-glycero-2-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (DPPE-PEG2000) lipid-based microbubbles could help treat myocardial infarction in a rat
model.121 They demonstrated both enhanced mesenchymal
stem cell transplantation efficiency (up to 4-fold) as well as
increased angiogenesis (up to 2.5-fold) in response to
insonation.121 Additionally, Kim et al. showed successful recovery of luminal area in a rat model of vasospasm following
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subarachnoid hemorrhage by insonating (1 MHz, 0.3 MPa,
60 seconds) echogenic liposomes (DSPE, 1,2-dioleoyl-sn-glycero-3-phosphocholine, and cholesterol, 60 : 30 : 10 ratio, plus
6% DPPE-PEG2000) loaded with nitric oxide and argon in a 1 : 9
ratio.122
Studies have shown that small molecules, such as genes and
peptides, can be eﬀectively delivered to the intracellular space
when administered with UCA and focused insonation causing
cavitation-induced permeability.27,123–125 For example, Dewitte
et al. describe the development of mRNA-loaded lipid microbubbles with a perfluorobutane core stabilized by a DPPC and
DSPE-PEG3400-biotin shell, and demonstrated the ability to
visualize these carriers using contrast ultrasound in a canine
model, suggesting the potential for these agents to be used for
UTDD applications in gene therapy.126 Also, a new emerging
technology is the development of lipoplexes and polyplexes,
where lipid-based microbubbles can be ligated with a complex
of nucleic acid and liposome or polymer, respectively, in order
to load and deliver nucleic acids and take advantage of
ultrasound-induced transfection enhancement.127,128
In another application, lysozyme-shelled microbubbles carrying minoxidil combined with insonation (1 MHz, 3 W cm 2,
0.266 MPa) enhanced hair follicle growth in a mouse model.129
They demonstrated approximately 66% increased hair follicle
growth rates using the minoxidil-loaded lysozyme microbubbles with ultrasound, which was significant compared to control groups.129 Similarly, Liao et al. used ultrasound-sensitive
lysozyme-shelled microbubbles to deliver adapalene to a mouse
model of photoaging skin, resulting in significant wrinkle
reduction with in the mice treated with this UTDD agent and
insonation (1 MHz, 3 W cm 2 for 1 minute).130
Microbubbles and ultrasound have also been investigated
for applications in drug delivery to the eye, including temporary
disruption of the blood–retina barrier, increased cellular
uptake, and targeted delivery.131 For example, Thakur et al.
have recently developed ultrasound-responsive rhodaminetagged nanobubbles that, when exposed to ultrasound
(1 MHz, 0–2.5 W cm 2, 60 seconds), significantly increased
the penetration depth (up to 5-fold) into ex vivo bovine and
porcine eyes.132 Also, Du et al. achieved 18% trans-retinal siRNA
transfection efficiency (6-fold increase compared to control)
using UTMD (1 MHz, 2 W cm 2, 5 minutes) in a rat model.133
Notably, for all studies discussed, cellular uptake and drug
eﬃcacy was significantly increased when ultrasound-induced
microbubble cavitation was included in the delivery method,
further supporting the importance of insonation for improving
drug delivery.

Phase-change agents for delivery
Phase-change agents are stabilized liquid emulsions that, when
insonated with certain ultrasound parameters, undergo a
phase-transition to a gaseous state accompanied by a volumetric expansion through a process known as acoustic droplet
vaporization (ADV).134 ADV is similar to cavitation of gaseous
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microbubbles via ultrasound, but there are some key diﬀerences. ADV involves liquid bubbles with boiling points near or
below body temperature, with perfluorocarbons (PFCs) being a
popular choice.135 These bubbles transition from liquid to gas
with insonation depending on the vapor pressure of the liquid
and the temperature achieved by the insonation.136 As the
ultrasound frequency and Laplace pressure decrease and the
duty cycle and peak negative pressure amplitude increase,
the ADV events will increase.135 Such acoustic droplets were
initially engineered because of the limitations of microbubbles,
which are too large to cross blood vessel walls, whereas acoustic
droplets are submicron in scale and have more extensive
access. These advantages of acoustic droplets are highly valuable for therapeutic avenues; for example, these particles may
penetrate deep into a tumor mass for drug delivery.136
Nanoemulsion-based ADVs, which are kinetically stable dispersions of two immiscible oil and water phases together with
surfactant molecules, are another emerging technology with
applications in UTDD.137 These locally-created microbubbles
are then subject to cavitation, promoting ultrasound-triggered
release of any encapsulated drug.137
Another particular phase-change-based approach to UTDD
aiming to overcome the limitations of conventional systems is
Acoustic Cluster Therapy (ACT).138 In this technique, a dispersion of microbubble/microdroplet clusters is formed by reconstituting the UCA microbubble with liquid oil microdroplets
and then injected intravenously.138 The microdroplet oil component is designed to have a relatively low boiling point
(o50 1C), with an ensuing high vapor pressure at body temperature, and low solubility in blood (o1  10 4 M). In one
example, ACT was achieved by reconstituting Sonazoid along
with perfluoromethylcyclopentane microdroplets stabilized
with a DSPC membrane.138 Upon activation by low power
ultrasound (MI o 0.4), the microdroplets transition into their
gas phase and transfer the gas to the microbubble, forming
larger bubbles that transiently lodge themselves in the microvasculature. Further insonation of the large (420 mm) activated
bubbles induces biomechanical eﬀects, due to their close contact with the endothelial wall, and improves drug delivery.138
Phase change agents can also be incorporated into a matrix,
such as a hydrogel, for increased stability and spatiotemporal
control of release. Hydrogels are three-dimensional, crosslinked networks of water-soluble polymers that oﬀer tunable
physical and chemical properties, allowing a wide range of
options for drug loading and delivery.139–141 The drug contained within the system can be incorporated so that it is freely
available throughout the matrix, contained within particles that
are themselves uniformly dispersed through the matrix, or exist
as a gradient (e.g., the drug particles localized in the center of
the depot). One particular area of interest using hydrogel-based
UTDD is acoustically-responsive scaffolds (ARSs), which are
hydrogels that house emulsions responsive to ADV.142,143
Cancer-related and infection-related delivery
Phase-change agents have been explored for disrupting bacterial biofilms as well as cancerous tissues. Other phase-change
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contrast agents (typically liquid PFC droplet stabilized by a
phospholipid shell) with 100–400 nm diameters have also
been used to enhance antibiotic efficacy against biofilms
by up to 94%.37 Rapoport et al. describe development of
ultrasound-activated, paclitaxel-carrying, PEG-PLLA nanoemulsions that convert into microbubbles upon insonation (1 MHz,
3.4 W cm 2) for cancer treatment. This ultrasound-triggered
nanotherapy causes tumor regression by an order of magnitude
in ovarian, breast, and orthotopic pancreatic cancer mouse
models.144 Additionally, de Matos et al. demonstrated effective
UTDD (1.3 MHz, 2–24 MPa, 1 minute) of mistletoe lectin-1
against a mouse model of colon cancer using a PFC nanoemulsion
encapsulated
within
DPPC/cholesterol/DSPE-PEG
liposomes.145 The ACT concept has been used in combination
with Abraxane, DOX, and irinotecan to successfully treat subcutaneous tumors of human prostate, breast, and colon cancer,
respectively, in mice.146–148 Recently, it was announced that a
Phase I trial of ACT (i.e., Sonazoid conjugated with liquid oil
microdroplets) in patients with liver metastases of gastrointestinal origin is underway in the United Kingdom.149
Other applications
Phase-change agents have also been used for angiogenesis and
wound healing, as well as temporary disruption of the BBB for
enhanced drug delivery. For example, promotion of angiogenesis was achieved with UTDD using HIFU (2.5 MHz) of a basic
fibroblast growth factor payload housed within a water-in-PFCin-water emulsion encased in a fibrin-based ARS that also
contained endothelial cells and fibroblasts surrounding the
payload core (0.25% and 1% v/v).150 For endothelial network
formation, both a higher volume of growth factor-loaded emulsion and acoustic pressure improved results (Fig. 7).150 Total
tubule length was statistically longer for the 1% growth factorloaded emulsion vs. the 0.25% formulation at both 3.3 MPa and
8 MPa, and total tubule length was also longer for the 8.8 MPa
samples for both the 0.25% and 1% emulsions compared to
their 3.3 MPa counterparts.150

Fig. 7 Results from insonation of the gel-in-gel ARS construct for UTDD
of basic fibroblast growth factor at 7 days post-insonation. Macroscopic
bubble formation was observed in all insonated samples except the 0.25%
emulsion exposed to 3.3 MPa, and no bubbles were formed in the absence
of ultrasound. Scale bar = 2 cm. Reprinted (modified) with permission from
ref. 150.
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Another study by this group looked at single and dual drug
release, using basic fibroblast growth factor and plateletderived growth factor with dextran payloads, via ADV from
fibrin-based ARSs using standing wave field ultrasound
(2.5 MHz for single payload, 3.25 MHz and 8.6 MHz for dual
payload).142 In this study, the possibility of staged drug delivery
was important because of the temporal control of angiogenesis
by diﬀerent growth factors.142 The use of a standing wave field
produced elevated amplitudes through constructive superposition without using high acoustic input energies. The authors
found that higher excitation frequencies were better suited for
spatial selectivity with the downside of prolonged insonation
period. ACT has also been used to safely and temporarily open
the BBB, using an acoustic power 5–10 times lower than those
applied for conventional microbubbles (i.e., within the diagnostic range).151 Using these conditions, small (Gadodiamide,
591.67 Da) and large (IRDye 800CW-PEG, B45 kDa) molecules
have been successfully delivered into the brain.151 Interestingly,
Wu et al. utilized lipid-based nanodroplets with octafluoropropane and decafluorobutane cores without an additional carrier
to disrupt and cross the BBB to deliver protein-sized molecules
to a mouse brain.152 Overall, phase-change agents represent an
intriguing vehicle for UTDD applications.

Other stimulus-responsive delivery
methods
Outside of microbubbles, there are also some interesting,
emerging devices and systems using cavitation to achieve
localized UTDD. One area that has recently gained attention
is ultrasound-activated drug delivery devices, whether implantable or transdermal. Delaney et al. developed an implantable
polymeric reservoir that can be incorporated into existing
spinal fusion hardware to provide additional antibiotic prophylaxis following spinal fusion surgery.51,153 Briefly, the reservoir
is 3D-printed out of polyether ether ketone (PEEK), the hollow
inside of the device is filled with a vancomycin solution, and
the reservoir is sealed with a thin layer of PLA film. Later,
exposure to ultrasound induces cavitation with rupture of the
film, which allows for localized release of the encapsulated
prophylactic antibiotic at the surgical site.153 We have shown
that insonation in Doppler mode (1.7 MHz frequency, 6.4 kHz
pulse repetition frequency, 100% output power) achieved eﬀective rupture of the PLA film and subsequent release of the
vancomycin payload in a cadaveric rabbit model of spinal
infection.153 Such a device has broad applicability, as the
reservoir could be loaded with a variety of drugs or factors. In
a slightly diﬀerent approach, Myers et al. designed ultrasoundsensitive polymeric cups for the targeted delivery of oncolytic
viruses to cancers.154 These cups, comprised of methyl methacrylate, hydroxyethyl methacrylate, and divinyl benzene, delivered the vaccinia virus to HepG2 and SKOV-3 mouse xenografts.
Insonation (0.5 MHz, 1.5 MPa peak negative pressure, 5% duty
cycle, 10 minutes) induced cavitation of the cups, causing
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10 000-fold and 1000-fold enhancement of delivery,
respectively.154
Thermo-responsive materials have also garnered attention
in the field of UTDD. While this review has already discussed
the mechanical eﬀects on liposomes, microbubbles, and other
agents, this section will focus on the thermal eﬀects of insonation on drug delivery. One of the most commonly studied
thermo-responsive vehicles for UTDD is a temperaturesensitive liposome, which locally release their payloads under
mild hyperthermic conditions produced by insonation with
focused ultrasound.155 Aside from liposomes, other thermoresponsive polymers have also been used to create microbubbles and micelles for thermo-responsive UTDD applications.
Recently, Huang et al. developed microbubbles with a
thermo-responsive shell made from poly(N-isopropylacrylamide)
(PNIPAM).156 These microbubbles release gemcitabine under the
mild hyperthermia induced by insonation (3 MHz, 2 W cm 2, duty
cycle of 50%, 1 minute) and have demonstrated therapeutic eﬃcacy
(10% apoptosis) in orthotopic pancreatic tumor models in mice,
suggesting that this platform could be useful for UTDD in conjunction with thermal ablation of cancerous tumors.156 Additionally,
Liang et al. designed HIFU thermosensitive cerasomes by combining cerasome-forming lipid with conventional lipids (DPPC and
DSPE-PEG) to create a drug-carrying vehicle that is highly stable at
37 1C with an 8-times increase in blood circulation time, but
releases its payload at 42 1C under HIFU exposure (0.5 MHz, duty
cycle 30%, 190 mV, 5 minutes) and provides significant inhibition of
MDA-MB-231 breast cancer tumors in mice, with B3-fold reduction
in tumor volume compared to controls.157 However, these mildhyperthemia-triggered liposomes are highly susceptible to instability
during circulation, which can lead to significant oﬀ-target release of
the drug payload.155 Therefore, researchers have begun exploring
alternatives, such as liposomes that react in the presence of higher
local temperature changes, such as those generated by HIFU. Using
commercially available thermosensitive liposomal DOX (ThermoDox), Dromi et al. found that 50% of the loaded DOX was released
in vitro in response to local hyperthermia (42 1C) produced by
pulsed HIFU exposure (1300 W cm 2, duty cycle 10%,
15–20 minutes), as well as up to 4-fold greater DOX release in an
in vivo mouse model of breast cancer compared to nonthemosensitive liposomal DOX (Doxil).158 Excitingly, Lyon et al. have
published results from a Phase 1 human clinical trial (TARDOX)
evaluating the safety and feasibility of UTDD of ThermoDOX for
treatment of liver tumors.159 Results suggest that their methods
were safe, clinically feasible, and importantly, as shown in Fig. 8,
effective in enhancing intratumoral drug delivery by almost 4 times
following insonation with focused ultrasound (0.96 MHz with duty
cycle and power tailored to each patient using a predictive model to
achieve 39.5–43 1C at the target site).159
Several recent studies have harnessed the various mechanistic advantages of ultrasound to induce or create favorable
conditions for drug delivery. For example, Sciurti et al. describe
the design of PLGA-microPlates for ultrasound-augmented
transdermal drug delivery, where the plates are composed of
square PLGA microparticles loaded with curcumin.160 This
group found that application of 1 MHz ultrasound to the
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microbeads (2 wt%), which, when compared to the gaseous
microbubbles, have the advantage of superior stability in vivo.16
To enhance release, these microbeads were also loaded with
tungsten particles (0.5–3 mm diameter; 0, 1, and 3 wt%), that,
due to their high acoustic impedance, induce vibration within
the microbeads. Using this system, release of fluorescent silica
nanoparticles increased by up to 30% following insonation
(20 kHz, up to 3 minutes). This alternative use of hydrogels
for UTDD may be particularly valuable for long term drug
release that may go beyond the stability period of
microbubbles.16

Conclusions

Fig. 8 Fluorescence microscopy images of target tumor biopsy samples
showing enhanced drug delivery to liver tumors before (left) and after
(right) UTDD. Top row: H&E stain demonstrating areas of necrosis within
the viable tumor tissue following UTDD. Middle row: Cell viability fluorescence imaging with DAPI (blue), cytokeratin-8 (green), and CD31 (red),
showing poor staining in the necrotic areas corresponding with the H&E
images. Bottom row: DOX distribution imaging with DAPI (blue) and DOX
(red), showing the absence of DOX prior to treatment (left) and nuclear
uptake of DOX following insonation (right). Reprinted with permission
from ref. 159.

microplate resulted in a 200% increase in curcumin release
after 30 minutes of insonation, compared to uninsonated
controls, suggesting a broad platform for an ultrasoundsensitive matrix filled with drugs for augmented transdermal
delivery.160 Another system recently designed by Zykova et al.
used an ultrasound-activated array of polymeric drug-loaded
microchambers as a depot system for implant coatings, specifically as an endovascular stent cover.161 Using a 1 wt% PLA
solution, this group constructed microchamber arrays housing
Rhodamine B as a model drug. Exposure of these arrays to lowfrequency ultrasound (20 kHz) triggered approximately 55%
drug release within 25 seconds.161
Ultrasound-mediated drug delivery to the eye has been
gaining attention in recent years, with several studies evaluating the safety and eﬃcacy of this technique.162 For example,
Allison et al. demonstrated quadrupled transcorneal delivery of
natamycin in an ex vivo rabbit cornea model of fungal keratitis
using ultrasound (0.5 W cm 2, 400 kHz, 5 minutes) compared
to controls.163 In one of the most recent in vivo studies, Nabili
et al. exhibited almost triple the penetration and delivery of
dexamethasone to the aqueous humor of a rabbit using ultrasound (400 kHz, 0.8 W cm 2, 5 minutes) compared to passive
controls.164
While hydrogels were previously discussed as scaﬀolds for
cavitation nuclei, they can also be designed as an acousticallyresponsive material.16 Kubota et al. used solid alginate
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UTDD impacts the treatment of diseases ranging from Alzheimer’s disease to cancer. The power of this approach has
become apparent as nano- and microparticle drug delivery
has been integrated with the ability to rupture these particles
in a focused manner at the site of interest. This external
triggering of drug delivery has also been exploited in various
materials that respond to diagnostic or therapeutic ultrasound.
With the recent advances in use of ultrasound to open up areas
previously inaccessible to drug delivery, e.g., delivery through
the BBB, the potential of UTDD is oﬀering new methods to
release drugs, permeabilize the site of drug delivery, and even
allow the drug to reach previously privileged sites.
In this review, we have provided a brief overview of these
methods and their dependence on ultrasound-responsiveness
of the material properties. Importantly, human trials using a
variety of these approaches have recently begun, demonstrating
the ability to translate these techniques clinically. As increasingly sophisticated materials are created, their coupling with
ultrasound to allow physician-controlled site- and timedependent triggering oﬀers new methods for non-invasive
control of drug delivery.
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